Dynavax Technologies | DVAX - Cost Of Sales


Dynavax Technologies reported $14.4M in Cost of Sales for its fiscal quarter ending in September of 2025.



Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Adma Biologics USD 50.4M 8.24M Dec/2025
Agenus USD 642K 399K Sep/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
TG Therapeutics USD 38.14M 10.05M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025